Predictive role of gene polymorphisms affecting thrombin-generation pathway in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration

Recent Patents on DNA and Gene Sequences

Volumn 3, Issue 2, 2009, Pages 114-122

  Parmeggiani, Francesco ^a   Gemmati, Donato ^a   Costagliola, Ciro ^a   Sebastiani, Adolfo ^a   Incorvaia, Carlo ^a  

^a NONE

Author keywords

Age related macular degeneration; Choroidal neovascularization; Pharmacogenetics; Photodynamic therapy with verteporfin; Single nucleotide polymorphisms; Thrombin generation pathway; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; FIBRINOLYTIC FACTOR; HYPERFIBRINOLYTIC FACTOR XIII A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PROTHROMBIN; THROMBIN; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VERTEPORFIN; BLOOD CLOTTING FACTOR 5; PORPHYRIN;

ACTIVATED PROTEIN C RESISTANCE; AMINO ACID SUBSTITUTION; BLOOD CLOTTING; CAUCASIAN; CHOROID CAPILLARY LAYER; DNA POLYMORPHISM; FOUNDER EFFECT; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE MUTATION; GENETIC RISK; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; PATIENT SELECTION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA CLEAVAGE; RNA STABILITY; SUBRETINAL NEOVASCULARIZATION; THROMBIN PRODUCTION; THROMBOPHILIA; THROMBOSIS; VASCULAR ENDOTHELIUM; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PATHOLOGY; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION;

CHOROIDAL NEOVASCULARIZATION; FACTOR V; HUMANS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; POLYMORPHISM, GENETIC; PORPHYRINS; PROTHROMBIN; THROMBIN;

EID: 70349231366     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221509788654151     Document Type: Review

References (98)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82: 844-851.
2. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004; 137: 486-495.
3. Hoh, J., Dewan, A.: WO2008013893 (2008).
4. Weinstock, J., Paikowsky, S.J.: WO2008150954 (2008).
5. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials - TAP Report No. 1. Arch Ophthalmol 1999; 117: 1329-1345.
6. Verteporfin in Photodynamic Therapy (VIP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in age related macular degeneration: 2 year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - VIP Report No. 2. Am J Ophthalmol 2001; 131: 541-560. (Pubitemid 32427660)
7. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: Update. Retina 2005; 25: 119-134. (Pubitemid 40365934)
8. Chakravarthy U, Soubrane G, Bandello F, et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol 2006; 90: 1188-1196. (Pubitemid 44351155)
9. Macular Photocoagulation Study group. Evaluation of argon green vs krypton red laser for photocoagulation of subfoveal choroidal neovascularization in the macular photocoagulation study. Arch Ophthalmol 1994; 112: 1176-1184.
10. Virgili G, Bini A. Laser photocoagulation for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2007; 3: CD004763.
11. Wickens J, Blinder KJ. A preliminary benefit-risk assessment of verteporfin in age-related macular degeneration. Drug Saf 2006; 29: 189-199. (Pubitemid 43363832)
12. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816.
13. Rosenfeld PJ, Brown DM, Heier JS, et al. Marina Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431. (Pubitemid 44511557)
14. Kaiser PK. Antivascular endothelial growth factor agents and their development: Therapeutic implications in ocular diseases. Am J Ophthalmol 2006; 142: 660-668.
15. Dadgostar H, Waheed N. The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Eye 2008; 22: 761-767. (Pubitemid 351850511)
16. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000; 45: 195-214. (Pubitemid 30947875)
17. Schlotzer-Schrehardt U, Viestenz A, Naumann GO, et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 2002; 240: 748-757. (Pubitemid 36104156)
18. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 2002; 43: 830-841. (Pubitemid 34184504)
19. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 2003; 44: 2147-2154. (Pubitemid 36520311)
20. Schmidt-Erfurth U, Niemeyer M, Geitzenauer W, Michels S. Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmology 2005; 112: 2061-2069. (Pubitemid 41720981)
21. Spaide RF. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 2006; 141: 149-156. (Pubitemid 43016187)
22. Zuluaga MF, Mailhos C, Robinson G, et al. Synergies of VEGF inhibition and photodynamic therapy in the treatment of age-related macular degeneration. Invest Ophthalmol Vis Sci 2007; 48: 1767-1772. (Pubitemid 351261364)
23. Bradley J, Ju M, Robinson GS. Combination therapy for the treatment of ocular neovascularization. Angiogenesis 2007; 10: 141-148. (Pubitemid 46440632)
24. Schmidt-Erfurth UM, Pruente C. Management of neovascular age-related macular degeneration. Prog Retin Eye Res 2007; 26: 437-451. (Pubitemid 46756380)
25. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007; 114: 1179-1185. (Pubitemid 46829388)
26. Antoszyk AN, Tuomi L, Chung CY, Singh A; Focus study group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): Year 2 results. Am J Ophthalmol 2008; 145: 862-874.
27. Blinder KJ, Bradley S, Bressler NM, et al. Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group; Verteporfin in Photodynamic Therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report 1. Am J Ophthalmol 2003; 136: 407-418.
28. Axer-Siegel R, Ehrlich R, Yassur Y, et al. Photodynamic therapy for age-related macular degeneration in a clinical setting: visual results and angiographic patterns. Am J Ophthalmol 2004; 137: 258-264. (Pubitemid 38220997)
29. Arias L, Pujol O, Berniell J, et al. Impact of lesion size on photodynamic therapy with verteporfin of predominantly classic lesions in age related macular degeneration. Br J Ophthalmol 2005; 89: 312-315. (Pubitemid 40327615)
30. Manku KK, Rotchford A, Whitaker J, Amoaku WM. Factors influencing poor visual outcome in patients treated with photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration. Clin Exp Ophthalmol 2007; 35: 330-334.
31. Parmeggiani F, Costagliola C, Gemmati D, et al. Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration. Pharmacogenet Genomics 2007; 17: 1039-1046. (Pubitemid 351339488)
32. Parmeggiani F, Costagliola C, Gemmati D, et al. Coagulation-balance genetic predictors for efficacy of photodynamic therapy in occult choroidal neovascularization secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 2008; 49: 3100-3106.
33. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992; 55: 145-157.
34. Hasan T, Parrish JA. Photodynamic therapy of cancer. Cancer medicine. In: Holland JF, Ed. Williams & Wilkins 1997; 739-751.
35. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst 1998; 90: 889-905.
36. Swartling, J., Johansson, A., Axelsson, J.: WO2008062000 (2008).
37. Roeder, B., Ermilov, E., Jux, N., Jasinski, S.: EP1834955A1 (2007).
38. Hamblin, MR., Mroz, P.: WO2008136906 (2008).
39. Kanani PM, Sinkey CA, Browning RL, et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999; 100: 1161-1168.
40. Schwahn B, Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene: Clinical consequences. Am J Pharmacogenomics 2001; 1: 189-201.
41. Volanti C, Matroule JY, Piette J. Involvement of oxidative stress in NF-kappab activation in endothelial cells treated by photodynamic therapy. Photochem Photobiol 2002; 75: 36-45.
42. Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab 2005; 6: 27-36. (Pubitemid 40277879)
43. Castro R, Rivera I, Blom HJ, Jakobs C, Tavares de Almeida I. Homocysteine metabolism hyperhomocysteinaemia and vascular disease: An overview. J Inherit Metab Dis 2006; 29: 3-20.
44. Parmeggiani F, Costagliola C, Incorvaia C, et al. Vision loss after PDT. Ophthalmology 2006; 113: 157.
45. Parmeggiani F, Gemmati D, Costagliola C, Sebastiani A, Incorvaia C. Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration. Pharmacogenomics 2009; 10: 81-95.
46. Zöller B, García de Frutos P, Hillarp A, Dahlbäck B. Thrombophilia as a multigenic disease. Haematologica 1999; 84: 59-70.
47. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517-1530.
48. Castoldi E, Rosing J. Factor V. Leiden: A disorder of factor V anticoagulant function. Curr Opin Hematol 2004; 11: 176-181. (Pubitemid 38952006)
49. Danckwardt S, Hartmann K, Gehring NH, Hentze MW, Kulozik AE. 3' end processing of the prothrombin mRNA in thrombophilia. Acta Haematol 2006; 115: 192-197.
50. Ye Z, Liu EH, Higgins JP, et al. Seven haemostatic gene polymorphisms in coronary disease: Meta-analysis of 66,155 cases and 91,307 controls. Lancet 2006; 367: 651-658. (Pubitemid 43289155)
51. Dahlbäck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008; 112: 19-27.
52. Ariens RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 2002; 100: 743-754.
53. Shemirani AH, Haramura G, Bagoly Z, Muszbek L. The combined effect of fibrin formation and factor XIII A subunit Val34Leu polymorphism on the activation of factor XIII in whole plasma. Biochim Biophys Acta 2006; 1764: 1420-1423. (Pubitemid 44279571)
54. Bressler NM. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol 2001; 119: 198-207.
55. Bernardi F, Marchetti G. Modulation of thrombophilia genes by environmental factors. Pathophysiol Haemost Thromb 2002; 32: 335-337.
56. Press RD, Bauer KA, Kujovich JL, Heit JA. Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 2002; 126: 1304-1318.
57. Mcglennen RC, Key NS. Clinical and laboratory management of the prothrombin G20210A mutation. Arch Pathol Lab Med 2002; 126: 1319-1325. (Pubitemid 36237282)
58. Zoller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524. (Pubitemid 24379631)
59. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008. (Pubitemid 23053939)
60. Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994; 91: 1396-1400. (Pubitemid 24059018)
61. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67. (Pubitemid 24144355)
62. Gemmati D, Serino ML, Moratelli S, et al. Coexistence of factor V G1691A and factor II G20210A gene mutations in a thrombotic family is associated with recurrence and early onset of venous thrombosis. Haemostasis 2001; 31: 99-105. (Pubitemid 34701656)
63. Rosendorff A, Dorfman DM. Activated protein C resistance and factor V Leiden: A review. Arch Pathol Lab Med 2007; 131: 866-871. (Pubitemid 46906378)
64. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-18738. (Pubitemid 24226180)
65. Zivelin A, Griffin JH, Xu X, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997; 89: 397-402. (Pubitemid 27051673)
66. Nicolaes G, Thomassen M, Tans G, et al. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC resistant individuals. Blood Coagul Fibrinolysis 1997; 8: 28-38. (Pubitemid 27156097)
67. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 39-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
68. Zivelin A, Rosenberg N, Faier S, et al. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood 1998; 92: 1119-1124. (Pubitemid 28369023)
69. Soria JM, Almasy L, Souto JC, T, et al. Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood 2000; 95: 2780-2785. (Pubitemid 30235884)
70. Butenas S, van't Veer C, Mann KG. "Normal" thrombin generation. Blood 1999; 94: 2169-2178.
71. Gehring NH, Frede U, Neu-Yilik G, et al. Increased efficiency of mRNA 3′ end formation: A new genetic mechanism contributing to hereditary thrombophilia. Nat Genet 2001; 28: 389-392. (Pubitemid 32702432)
72. Carter AM, Sachchithananthan M, Stasinopoulos S, Maurer F, Medcalf RL. Prothrombin G20210A is a bifunctional gene polymorphism. Thromb Haemost 2002; 87: 846-853. (Pubitemid 34516613)
73. Howard TE, Meng X, Meszane M, Robida AM, Xu K. The G20210A mutation increases stability of the prothrombin (f-II) mRNA; possible mechanism for increased plasma f-II levels and thrombotic risk. Blood 2001; 259a: [Abstract].
74. Hehlgans S, vonder D, Döhner U, Unkrik C, Pötsch B. Turnover of prothrombin mRNA is not influenced by the 20210 polymorphism. Thromb Haemost 1999; 403: [Abstract].
75. Pollak ES, Lam HS, Russell JE. The G20210A mutation does not affect the stability of prothrombin mRNA in vivo. Blood 2002; 100: 359-362. (Pubitemid 35177472)
76. Ceelie H, Spaargaren-van Riel CC, Bertina RM, Vos HL. G20210A is a functional mutation in the prothrombin gene: Effect on protein levels and 3'-end formation. J Thromb Haemost 2004; 2: 119-127. (Pubitemid 40185628)
77. Hézard N, Bouaziz-Borgi L, Remy MG, Nguyen P. Utility of thrombin-generation assay in the screening of factor V G1691A (Leiden) and prothrombin G20210A mutations and protein S deficiency. Clin Chem 2006; 52: 665-670.
78. Simioni P, Tormene D, Spiezia L, et al. Inherited thrombophilia and venous thromboembolism. Semin Thromb Hemost 2006; 32: 700-708.
79. Varga EA. Genetic counseling for inherited thrombophilias. J Thromb Thrombolysis 2008; 25: 6-9.
80. Rosendaal FR. Venous thrombosis: The role of genes, environment, and behavior. Hematol Am Soc Hematol Educ Program 2005: 1-12.
81. Arnold JJ, Blinder KJ, Bressler NM, et al. Treatment of age-related macular degeneration with photodynamic therapy study group; Verteporfin in photodynamic therapy study group. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: Case reports from randomized clinical trials - TAP and VIP report no. 3. Am J Ophthalmol 2004; 137: 683-696.
82. Isola V, Pece A, Parodi MB. Choroidal ischemia after photo-dynamic therapy with verteporfin for choroidal neovascularization. Am J Ophthalmol 2006; 142: 680-683. (Pubitemid 44442046)
83. Azab M, Boyer DS, Bressler NM, et al. Visudyne in minimally classic choroidal neovascularization study group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005; 123: 448-457.
84. Chan WM, Lai TY, Tano Y, et al. Photodynamic therapy in macular diseases of Asian populations: When East meets West. Jpn J Ophthalmol 2006; 50: 161-169.
85. Yang N, Fan CM, Ho CK. Review of first year result of photodynamic therapy on age-related macular degeneration in Chinese population. Eye 2006; 20: 523-526. (Pubitemid 43674986)
86. Brown GC, Brown MM, Campanella J, Beauchamp GR. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration - A value-based reappraisal with 5-year data. Am J Ophthalmol 2005; 140: 679-687.
87. Colquitt JL, Jones J, Tan SC, et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: A systematic review and economic evaluation. Health Technol Assess 2008; 12: 1-222.
88. Brown MM, Brown GC, Brown HC, Peet J. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 2008; 115: 1039-1045. (Pubitemid 351749692)
89. Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology 2007; 114: 1170-1178. (Pubitemid 46829369)
90. Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): Modelling cost effectiveness. Br J Ophthalmol 2007; 91: 1244-1246. (Pubitemid 47344908)
91. Waisbourd M, Loewenstein A, Goldstein M, Leibovitch I. Targeting vascular endothelial growth factor: A promising strategy for treating age-related macular degeneration. Drugs Aging 2007; 24: 643-662.
92. Cruess AF, Zlateva G, Xu X, et al. Economic burden of bilateral neovascular age-related macular degeneration: Multi-country observational study. Pharmacoeconomics 2008; 26: 57-73.
93. Schmidt-Erfurth U, Miller J, Sickenberg M, et al. Photodynamic therapy of subfoveal choroidal neovascularization: Clinical and angiographic examples. Graefes Arch Clin Exp Ophthalmol 1998; 236: 365-374. (Pubitemid 28192838)
94. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 1999; 117: 1161-1173.
95. Schmidt-Erfurth U, Miller JW, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: Results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 1999; 117: 1177-1187. (Pubitemid 29428826)
96. Dati F, Hafner G, Erbes H, et al. ProC Global: The first functional screening assay for the complete protein C pathway. Clin Chem 1997; 43: 1719-1723. (Pubitemid 27396375)
97. Sillero PL, Fernández de Velasco J, Loscertales J, Espinoza J, Soto C, Tomás JF. ProC global: An automated screening test for factor V Leiden and prothrombin mutation 20210 G to a detection. Thromb Res 2001; 101: 215-216.
98. Devreese K, Wijns W, Combes I, Van kerckhoven S, Hoylaerts MF. Thrombin generation in plasma of healthy adults and children: Chromogenic versus fluorogenic thrombogram analysis. Thromb Haemost 2007; 98: 600-613.